img

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Insights, Forecast to 2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare

Publisher : MRA | Format : PDF

Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Insights, Forecast to 2034

Progressive familial intrahepatic cholestasis (PFIC) type 2 is a rare genetic disorder that has no curative medication. Key players in the market only provide symptomatic treatment drugs.
Market Analysis and InsightsGlobal Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market
Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market is expected to reach to US$ 248 million in 2024, with a positive growth of %, compared with US$ 236 million in 2022 which suffered dual impact of COVID-19 and Russia-Ukraine War in the year. Backed with the increasing demand from downstream industries, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment industry is evaluated to reach US$ 340 million in 2029. The CAGR will be 5.4% during 2024 to 2029.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers
This report presents an overview of global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market from 2018 to 2029, aiming to help readers to get a comprehensive understanding of global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment market with multiple angles. Items like regional revenue from 2018 to 2029 and companies’ revenue and gross margin from 2018 to 2024 are analyzed. In addition, revenue of product type and application in each region from 2018 to 2029 are also highlighted.
Companies, Type, Application and Regions Listed in the Report



By Company


Teva
AbbVie
Glenmark Pharmaceuticals
Par Pharmaceuticals
Mylan
Sanofi
Novartis
Akorn
Albireo Pharma
Mirum Pharmaceuticals
Segment by Type
Ursodeoxycholic Acid
Cholestyramine
Rifampicin
Late Stage Pipeline Drugs
Others

Segment by Application


Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
China
Asia (excluding China)
Japan
South Korea
China Taiwan
Southeast Asia
India
Latin America, Middle East & Africa
Brazil
Mexico
Turkey
Israel
GCC Countries

Chapter Outline


Chapter 1Product definition, type and application introduction
Chapter 2Regional revenue analysis from 2018 to 2029
Chapter 3Detailed analysis of Product Name companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4Product revenue analysis by type from 2018 to 2029 globally
Chapter 5Product revenue analysis by application from 2018 to 2029 globally
Chapter 6Product revenue analysis by type and application from 2018 to 2029 in US & Canada. Product revenue analysis of each country in US & Canada from 2018 to 2029
Chapter 7Product revenue analysis by type and application from 2018 to 2029 in Europe. Product revenue analysis of each country in Europe from 2018 to 2029
Chapter 8Product revenue analysis by type and application from 2018 to 2029 in China. Product revenue analysis of China from 2018 to 2029
Chapter 9Product revenue analysis by type and application from 2018 to 2029 in Asia (excluding China). Product revenue analysis of each country in Asia (excluding China) from 2018 to 2029
Chapter 10Product revenue analysis by type and application from 2018 to 2029 in Middle East, Africa and Latin America. Product revenue analysis of each country in Middle East, Africa and Latin America from 2018 to 2029.
Chapter 11Companies’ outline, covering company’s basic information, major business, Progressive Familial Intrahepatic Cholestasis Type 2 Treatment introduction, etc. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue and Gross Margin of each company from 2018 to 2024
Chapter 12Mr Accuracy reports Conclusions of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment
Chapter 13Methodology and Data Sources adopted by Mr Accuracy reports

Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Ursodeoxycholic Acid
1.2.3 Cholestyramine
1.2.4 Rifampicin
1.2.5 Late Stage Pipeline Drugs
1.2.6 Others
1.3 Market by Application
1.3.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital Pharmacies
1.3.3 Retail Pharmacies
1.3.4 Online Pharmacies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Perspective (2018-2029)
2.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Trends by Region
2.2.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Region (2018-2024)
2.2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Region (2024-2029)
2.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Dynamics
2.3.1 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Trends
2.3.2 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
2.3.3 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges
2.3.4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Players
3.1.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2018-2024)
3.1.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Players (2018-2024)
3.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Ranking by Revenue, 2021 VS 2022 VS 2024
3.4 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio
3.4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2022
3.5 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Head office and Area Served
3.6 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application
3.7 Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Type
4.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Type (2018-2024)
4.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2024-2029)
5 Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Breakdown Data by Application
5.1 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Historic Market Size by Application (2018-2024)
5.2 Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
6.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
6.2.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024)
6.2.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)
6.2.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
6.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
6.3.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024)
6.3.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)
6.3.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
6.4 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
6.4.1 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024)
6.4.3 North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
7.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
7.2.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024)
7.2.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)
7.2.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
7.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
7.3.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024)
7.3.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)
7.3.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
7.4 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
7.4.1 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024)
7.4.3 Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
8.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
8.2.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024)
8.2.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)
8.2.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
8.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
8.3.1 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024)
8.3.2 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)
8.3.3 China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
9.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
9.2.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024)
9.2.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)
9.2.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
9.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
9.3.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024)
9.3.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)
9.3.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
9.4 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region
9.4.1 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2024)
9.4.3 Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type
10.2.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024)
10.2.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application
10.3.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024)
10.3.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country
10.4.1 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024)
10.4.3 Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Teva
11.1.1 Teva Company Details
11.1.2 Teva Business Overview
11.1.3 Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.1.4 Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.1.5 Teva Recent Developments
11.2 AbbVie
11.2.1 AbbVie Company Details
11.2.2 AbbVie Business Overview
11.2.3 AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.2.4 AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.2.5 AbbVie Recent Developments
11.3 Glenmark Pharmaceuticals
11.3.1 Glenmark Pharmaceuticals Company Details
11.3.2 Glenmark Pharmaceuticals Business Overview
11.3.3 Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.3.4 Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.3.5 Glenmark Pharmaceuticals Recent Developments
11.4 Par Pharmaceuticals
11.4.1 Par Pharmaceuticals Company Details
11.4.2 Par Pharmaceuticals Business Overview
11.4.3 Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.4.4 Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.4.5 Par Pharmaceuticals Recent Developments
11.5 Mylan
11.5.1 Mylan Company Details
11.5.2 Mylan Business Overview
11.5.3 Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.5.4 Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.5.5 Mylan Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Details
11.6.2 Sanofi Business Overview
11.6.3 Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.6.4 Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.6.5 Sanofi Recent Developments
11.7 Novartis
11.7.1 Novartis Company Details
11.7.2 Novartis Business Overview
11.7.3 Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.7.4 Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.7.5 Novartis Recent Developments
11.8 Akorn
11.8.1 Akorn Company Details
11.8.2 Akorn Business Overview
11.8.3 Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.8.4 Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.8.5 Akorn Recent Developments
11.9 Albireo Pharma
11.9.1 Albireo Pharma Company Details
11.9.2 Albireo Pharma Business Overview
11.9.3 Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.9.4 Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.9.5 Albireo Pharma Recent Developments
11.10 Mirum Pharmaceuticals
11.10.1 Mirum Pharmaceuticals Company Details
11.10.2 Mirum Pharmaceuticals Business Overview
11.10.3 Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Introduction
11.10.4 Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
11.10.5 Mirum Pharmaceuticals Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type (US$ Million), 2018 VS 2022 VS 2029
Table 2. Key Players of Ursodeoxycholic Acid
Table 3. Key Players of Cholestyramine
Table 4. Key Players of Rifampicin
Table 5. Key Players of Late Stage Pipeline Drugs
Table 6. Key Players of Others
Table 7. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application (US$ Million), 2018 VS 2022 VS 2029
Table 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2018-2024)
Table 11. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2024-2029)
Table 13. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Trends
Table 14. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Drivers
Table 15. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Challenges
Table 16. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Restraints
Table 17. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Players (2018-2024)
Table 19. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2022)
Table 20. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Industry Ranking 2021 VS 2022 VS 2024
Table 21. Global 5 Largest Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue (CR5 and HHI) & (2018-2024)
Table 22. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Headquarters and Area Served
Table 23. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application
Table 24. Global Key Players of Progressive Familial Intrahepatic Cholestasis Type 2 Treatment, Product and Application
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2018-2024)
Table 28. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Market Share by Type (2024-2029)
Table 30. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Application (2018-2024)
Table 32. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue Share by Application (2024-2029)
Table 34. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 35. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 36. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 37. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 38. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 39. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 40. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 41. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 42. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 43. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 44. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 45. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 46. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 47. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 48. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 49. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 50. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 51. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 52. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 53. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 54. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 55. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 56. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2029
Table 57. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2018-2024) & (US$ Million)
Table 58. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Region (2024-2029) & (US$ Million)
Table 59. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2018-2024) & (US$ Million)
Table 60. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Type (2024-2029) & (US$ Million)
Table 61. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2018-2024) & (US$ Million)
Table 62. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Application (2024-2029) & (US$ Million)
Table 63. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2029
Table 64. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2018-2024) & (US$ Million)
Table 65. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size by Country (2024-2029) & (US$ Million)
Table 66. Teva Company Details
Table 67. Teva Business Overview
Table 68. Teva Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 69. Teva Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 70. Teva Recent Developments
Table 71. AbbVie Company Details
Table 72. AbbVie Business Overview
Table 73. AbbVie Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 74. AbbVie Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 75. AbbVie Recent Developments
Table 76. Glenmark Pharmaceuticals Company Details
Table 77. Glenmark Pharmaceuticals Business Overview
Table 78. Glenmark Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 79. Glenmark Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 80. Glenmark Pharmaceuticals Recent Developments
Table 81. Par Pharmaceuticals Company Details
Table 82. Par Pharmaceuticals Business Overview
Table 83. Par Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 84. Par Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 85. Par Pharmaceuticals Recent Developments
Table 86. Mylan Company Details
Table 87. Mylan Business Overview
Table 88. Mylan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 89. Mylan Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 90. Mylan Recent Developments
Table 91. Sanofi Company Details
Table 92. Sanofi Business Overview
Table 93. Sanofi Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 94. Sanofi Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 95. Sanofi Recent Developments
Table 96. Novartis Company Details
Table 97. Novartis Business Overview
Table 98. Novartis Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 99. Novartis Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 100. Novartis Recent Developments
Table 101. Akorn Company Details
Table 102. Akorn Business Overview
Table 103. Akorn Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 104. Akorn Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 105. Akorn Recent Developments
Table 106. Albireo Pharma Company Details
Table 107. Albireo Pharma Business Overview
Table 108. Albireo Pharma Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 109. Albireo Pharma Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 110. Albireo Pharma Recent Developments
Table 111. Mirum Pharmaceuticals Company Details
Table 112. Mirum Pharmaceuticals Business Overview
Table 113. Mirum Pharmaceuticals Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Product
Table 114. Mirum Pharmaceuticals Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024) & (US$ Million)
Table 115. Mirum Pharmaceuticals Recent Developments
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Type, 2018 VS 2022 VS 2029 (US$ Million)
Figure 2. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type: 2022 VS 2029
Figure 3. Ursodeoxycholic Acid Features
Figure 4. Cholestyramine Features
Figure 5. Rifampicin Features
Figure 6. Late Stage Pipeline Drugs Features
Figure 7. Others Features
Figure 8. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size Growth Rate by Application, 2018 VS 2022 VS 2029 (US$ Million)
Figure 9. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application: 2022 VS 2029
Figure 10. Hospital Pharmacies Case Studies
Figure 11. Retail Pharmacies Case Studies
Figure 12. Online Pharmacies Case Studies
Figure 13. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Report Years Considered
Figure 14. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 15. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 16. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region: 2022 VS 2029
Figure 17. Global Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Players in 2022
Figure 18. Global Top Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment as of 2022)
Figure 19. The Top 10 and 5 Players Market Share by Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Revenue in 2022
Figure 20. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 21. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
Figure 22. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
Figure 23. North America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)
Figure 24. United States Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Canada Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 27. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
Figure 28. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
Figure 29. Europe Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)
Figure 30. Germany Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. France Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. U.K. Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Italy Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Russia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 35. Nordic Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 37. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
Figure 38. China Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
Figure 39. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 40. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
Figure 41. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
Figure 42. Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Region (2018-2029)
Figure 43. Japan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. South Korea Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. China Taiwan Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Southeast Asia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 47. India Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Australia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY (2018-2029) & (US$ Million)
Figure 50. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Type (2018-2029)
Figure 51. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Application (2018-2029)
Figure 52. Middle East, Africa, and Latin America Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Share by Country (2018-2029)
Figure 53. Brazil Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 54. Mexico Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 55. Turkey Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 56. Saudi Arabia Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 57. Israel Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 58. GCC Countries Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 59. Teva Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 60. AbbVie Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 61. Glenmark Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 62. Par Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 63. Mylan Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 64. Sanofi Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 65. Novartis Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 66. Akorn Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 67. Albireo Pharma Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 68. Mirum Pharmaceuticals Revenue Growth Rate in Progressive Familial Intrahepatic Cholestasis Type 2 Treatment Business (2018-2024)
Figure 69. Bottom-up and Top-down Approaches for This Report
Figure 70. Data Triangulation
Figure 71. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries